Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Front Endocrinol (Lausanne). 2020 Feb 18;11:61. doi: 10.3389/fendo.2020.00061. eCollection 2020.
Metastatic pheochromocytoma/paraganglioma (MPP) therapy mainly involves radionuclide therapy, chemotherapy, and targeted therapy. In recent years, temozolomide (TMZ) showed great promise in some MMP patients, especially those with germline mutation. We reported a patient with MPP who did not have any known germline genetic change and responded remarkably well to TMZ monotherapy. The patient was a 41-year-old woman with local and distant recurrence (soft tissues and bone metastases) of retroperitoneal paraganglioma. She suffered from dizziness, palpitation, sweating, weight loss and constipation, with the blood pressure fluctuating substantially from 130/100 mmHg to 190/120 mmHg, although she was on phenoxybenzamine and metoprolol medication. The patient showed clinical and radiological response after 3-cycle TMZ therapy. Upon 15 cycles of TMZ therapy, her symptoms were dramatically alleviated, urinary norepinephrine excretion decreased from 1,840 μg/24 h to 206 μg/24 h, and CT showed that the lesions further shrank. Molecular profiling of the tumor tissue of the patient revealed hypermethylation of the O6-methylguanine-DNA-methyltransferase () promoter and a negative immunostaining for MGMT. Globally, only 26 cases of MPP treated with TMZ have been described so far. TMZ is effective, especially in patients with mutation, which can be explained by the silencing of MGMT expression as a consequence of promoter hypermethylation in -mutated tumors. Although, in general, patients with mutation or MGMT promoter hypermethylation have better response to TMZ, there are also exceptions. Severe side effects are uncommon, with only 17.4% patients experiencing Grade 3 toxicities, including lymphopenia, and hypertension. TMZ is effective and safe in MPP patients, and, it may work better on patients with -related MPP. Measurement of MGMT expression might help assess the tumor sensitivity to TMZ but this needs further systematic investigation.
转移性嗜铬细胞瘤/副神经节瘤(MPP)的治疗主要包括放射性核素治疗、化疗和靶向治疗。近年来,替莫唑胺(TMZ)在一些 MPP 患者中显示出巨大的应用前景,特别是那些具有种系突变的患者。我们报告了一例 MPP 患者,该患者没有任何已知的种系遗传改变,对 TMZ 单药治疗反应良好。患者为 41 岁女性,患有腹膜后副神经节瘤局部和远处复发(软组织和骨转移)。她有头晕、心悸、出汗、体重减轻和便秘,血压波动较大,从 130/100mmHg 波动至 190/120mmHg,尽管她在服用酚芐明和美托洛尔。患者在接受 3 个周期 TMZ 治疗后表现出临床和影像学反应。在接受 15 个周期 TMZ 治疗后,她的症状明显缓解,尿去甲肾上腺素排泄从 1840μg/24h 降至 206μg/24h,CT 显示病变进一步缩小。患者肿瘤组织的分子谱分析显示 O6-甲基鸟嘌呤-DNA-甲基转移酶(MGMT)启动子的高甲基化和 MGMT 的免疫染色阴性。总的来说,目前为止仅描述了 26 例用 TMZ 治疗的 MPP 病例。TMZ 是有效的,特别是在 突变的患者中,这可以用 突变肿瘤中 MGMT 表达沉默来解释,这是由于 启动子的高甲基化所致。虽然一般来说, 突变或 MGMT 启动子高甲基化的患者对 TMZ 反应更好,但也有例外。严重的副作用并不常见,只有 17.4%的患者出现 3 级毒性,包括淋巴细胞减少和高血压。TMZ 对 MPP 患者有效且安全,并且可能对与 相关的 MPP 患者效果更好。MGMT 表达的测量可能有助于评估肿瘤对 TMZ 的敏感性,但这需要进一步的系统研究。